V21L (p.Val21Leu) variant of NTRK3 (NT-3 growth factor receptor)

V21L (p.Val21Leu) in NTRK3 (NT-3 growth factor receptor) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.23 / 1. The record also includes population frequency data and structural context.

V21L (p.Val21Leu) variant details